id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-031922-3pfxrhbc	Petrie, John R	SGLT2 inhibitors and renal complications in type 1 diabetes	2020-09-15		.txt	text/plain	1559	79	52	In this issue of The Lancet Diabetes & Endocrinology, Per-Henrik Groop and colleagues 4 report the effect of the SGLT2 inhibitor dapagliflozin on albuminuria in adults with type 1 diabetes in a post-hoc subgroup analysis of the DEPICT-1 and DEPICT-2 phase 3 trials. The UK National Institute for Healthcare Excellence (NICE) subsequently recommended both drugs (dapagliflozin in August, 2019, and sotagliflozin in February, 2020) to be cost-effective for use within the UK National Health Service for individuals who additionally had a relatively high insulin requirement (≥0·5 units/kg per day) and had completed an evidence-based qualityassured structured education programme. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials	./cache/cord-031922-3pfxrhbc.txt	./txt/cord-031922-3pfxrhbc.txt